Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12608000470392
Ethics application status
Approved
Date submitted
17/08/2005
Date registered
17/08/2005
Date last updated
30/11/2015
Type of registration
Retrospectively registered
Titles & IDs
Public title
A placebo controlled randomized trial of long-term antibiotics to prevent recurrent urinary tract infection in children
Query!
Scientific title
A trial of long term cotrimoxazole compared to placebo to prevent recurrent urinary tract infection in children
Query!
Secondary ID [1]
288034
0
nil known
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
PRIVENT
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Urinary tract infection
3718
0
Query!
Condition category
Condition code
Renal and Urogenital
3889
3889
0
0
Query!
Kidney disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Low dose continuous, daily, cotrimoxazole for 12 months. Oral route. Dose is calculated by volume according to body weight; 2mg/kg of Trimethoprim and 10mg/kg sulphamethoxazole. This works out to be 0.25mL/kg of 200-40mg/5mL suspension. Dose is increased every 3 months to the nearest 0.5mL as the child grows. Children take medication once per day for 12 months.
Query!
Intervention code [1]
3446
0
Prevention
Query!
Comparator / control treatment
Placebo, taste and colour matched to active. Oral route, once daily for 12 months. Placebo is liquid, colour and taste matched to active treatment. Made specifically for this trial by accredited laboratory. 0.25mL/kg as single daily dose, increased every 3 months to nearest 0.5mL. This is identical to the volume given in the active treatment arm.
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
4788
0
Repeat symptomatic microbiologically proven urinary tract infection. Measured by direct questioning of parents at 3, 6, 9 and 12 month clinic reviews. Any parent stating yes to a urinary tract infection is asked for consent to contact primary care giver and obtain details. Trial coordinators at each centre contact health providers and obtain a copy of microbioligucal report on the urine culture.
Query!
Assessment method [1]
4788
0
Query!
Timepoint [1]
4788
0
3, 6, 9 and 12 month followup
Query!
Secondary outcome [1]
8102
0
Febrile urinary tract infection. Measured by direct questioning of parent at 3,6,9 and 12 month time points and verified with appropriate health care providers record of microbiological result
Query!
Assessment method [1]
8102
0
Query!
Timepoint [1]
8102
0
Asked at 3, 6, 9 and 12 months. Covers the period 0-12 months
Query!
Secondary outcome [2]
8103
0
Hospitalisation. Measured by direct questioning of parent at 3,6,9 and 12 month time points
Query!
Assessment method [2]
8103
0
Query!
Timepoint [2]
8103
0
Asked at 3, 6, 9 and 12 months, covers the period 0-12 months
Query!
Secondary outcome [3]
8104
0
Adverse drug reactions. Measured by direct questioning of parent at 3,6,9 and 12 month time points. Questioned about occurrences of; diarrhoea, nausea, vomitting, rash, thrush, jaundice, anaphylaxis, haematoligic abnormalities
Query!
Assessment method [3]
8104
0
Query!
Timepoint [3]
8104
0
0-12 months, asked at 3, 6, 9 and 12 month reviews
Query!
Secondary outcome [4]
8105
0
Antibiotic administration for other infectious disease. Measured by direct questioning of parents at 3, 6, 9 and 12 month clinic reviews
Query!
Assessment method [4]
8105
0
Query!
Timepoint [4]
8105
0
0 -12 months, questioned at 3, 6, 9 and 12 month clinic review
Query!
Secondary outcome [5]
8106
0
Abnorrmalities on dimercaptosuccinic acid scan (DMSA). Children with abnormal initial DMSA scans are requested to undergo a repeat DMSA at 12 months. All DMSA scans are centrally re-reported by one Senior Staff Specialist in nuclear medicine at The Children's Hospital at Westmead (CHW). DMSA scans at 12 months are compared to initial scans and the single CHW reviewer codes the scans as to whether they are ; unchanged, partial improvement, complete improvement and no change.
Query!
Assessment method [5]
8106
0
Query!
Timepoint [5]
8106
0
Baseline, 12 months
Query!
Eligibility
Key inclusion criteria
Children <18 years, symptomatic microbiologically proven urinary tract infection
Query!
Minimum age
0
Days
Query!
Query!
Maximum age
18
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Asymptomatic urinary tract infection, Non-recurrent urinary tract infection in children > 5 years, Bag urine sample, growth below threshold, not pure growth, predisposing causes; indwelling catheter, nosocomial infection, urological/nephrological disease (renal disese, pelviureteric obstruction, vesicoureteral obstruction, posterior urethral valves, renal tract malformations, renal calculi), neurological problems (spina bifida, spina cord injuries, neurogenic bladder, cerebral palsy) Glucose 6 phosphate dehydrogenase deficiency, sulphur allergy, non-resident of Australia
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation by phone
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer generated randomisation by National Health and Medical Research Council (NHMRC) trial centre, Stratified by centre, referral course, frequency of prior UTIs, presen or absence of reflux, age and gender by the method of minimisation
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Taste and colour matched placebo. run-in period of active treament for 2 weeks. Compliance assesed prior to randomisation. Compliance measured by direct questioning and measured by amount of medication remaining in bottle at each 3 monthly review
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
1/12/1998
Query!
Actual
2/11/1998
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
29/03/2007
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
780
Query!
Accrual to date
Query!
Final
576
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment postcode(s) [1]
1159
0
1860
Query!
Recruitment postcode(s) [2]
1160
0
2037
Query!
Recruitment postcode(s) [3]
1161
0
2041
Query!
Recruitment postcode(s) [4]
1162
0
2037
Query!
Recruitment postcode(s) [5]
1163
0
2045
Query!
Recruitment postcode(s) [6]
1164
0
2037
Query!
Funding & Sponsors
Funding source category [1]
3900
0
Government body
Query!
Name [1]
3900
0
National Health and Medical Research Council (NHMRC) of Australia
Query!
Address [1]
3900
0
GPO Box 1421, Canberra, ACT 2601
Query!
Country [1]
3900
0
Australia
Query!
Funding source category [2]
3901
0
Charities/Societies/Foundations
Query!
Name [2]
3901
0
Financial Markets Foundation of Australia
Query!
Address [2]
3901
0
GPO Box 3655 Sydney NSW 1044
Query!
Country [2]
3901
0
Australia
Query!
Funding source category [3]
3902
0
Other
Query!
Name [3]
3902
0
JT Honan, Manildra Holdings
Query!
Address [3]
3902
0
Private Donation, Manildra Holdings Level 12, 72 Castlereagh Street, Sydney NSW, 2000
Query!
Country [3]
3902
0
Australia
Query!
Primary sponsor type
Hospital
Query!
Name
The Childrens Hospital at Westmead
Query!
Address
Locked bag 4001, Westmead, NSW 2145
Query!
Country
Australia
Query!
Secondary sponsor category [1]
3501
0
University
Query!
Name [1]
3501
0
University of Sydney
Query!
Address [1]
3501
0
Camperdown, NSW 2006
Query!
Country [1]
3501
0
Australia
Query!
Other collaborator category [1]
424
0
University
Query!
Name [1]
424
0
Australian National University Medical School
Query!
Address [1]
424
0
Frank Fenner Building 42, The Australian National University, Canberra, ACT 0200
Query!
Country [1]
424
0
Australia
Query!
Other collaborator category [2]
425
0
University
Query!
Name [2]
425
0
University of Queensland
Query!
Address [2]
425
0
Level 3 Foundation Building, Herston Road, Brisbane, Queensland 4029
Query!
Country [2]
425
0
Australia
Query!
Other collaborator category [3]
426
0
Hospital
Query!
Name [3]
426
0
Royal Childrens Hospital
Query!
Address [3]
426
0
50 Flemington Road, Parkville, Melbourne, Victoria 3052
Query!
Country [3]
426
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
5951
0
Royal Alexandra Hospital for Children, The New Childrens Hospital
Query!
Ethics committee address [1]
5951
0
Locked Bag 4001, Wetmead NSW 2145
Query!
Ethics committee country [1]
5951
0
Australia
Query!
Date submitted for ethics approval [1]
5951
0
05/12/1996
Query!
Approval date [1]
5951
0
20/12/1996
Query!
Ethics approval number [1]
5951
0
96081, renewed 2002/051
Query!
Ethics committee name [2]
5952
0
The University of Sydney Human research Ethics committee
Query!
Ethics committee address [2]
5952
0
Main Quadrangle, University of Sydney, Camperdown, NSW 2006
Query!
Ethics committee country [2]
5952
0
Australia
Query!
Date submitted for ethics approval [2]
5952
0
09/09/2001
Query!
Approval date [2]
5952
0
04/02/2002
Query!
Ethics approval number [2]
5952
0
01/09/26
Query!
Ethics committee name [3]
5953
0
Wentworth Area Health Service Ethics Committee
Query!
Ethics committee address [3]
5953
0
Court Buliding PO Box 63 Penrith NSW 2751
Query!
Ethics committee country [3]
5953
0
Australia
Query!
Date submitted for ethics approval [3]
5953
0
31/03/2004
Query!
Approval date [3]
5953
0
13/04/2004
Query!
Ethics approval number [3]
5953
0
03/016
Query!
Ethics committee name [4]
5954
0
Royal CHildrens Hospital, Melbourne Ethics in Human Research Committee
Query!
Ethics committee address [4]
5954
0
50 Flemington Road Parkville Victoria 3052
Query!
Ethics committee country [4]
5954
0
Australia
Query!
Date submitted for ethics approval [4]
5954
0
01/02/2002
Query!
Approval date [4]
5954
0
05/03/2002
Query!
Ethics approval number [4]
5954
0
22007A, 22007P
Query!
Ethics committee name [5]
5955
0
Royal Childrens Hospital and Health Service District Ethics Committee
Query!
Ethics committee address [5]
5955
0
RCH Foundation Building, Royal Childrens Hospital, Herston Road, Brisbane, Queensland 4029
Query!
Ethics committee country [5]
5955
0
Australia
Query!
Date submitted for ethics approval [5]
5955
0
01/04/2005
Query!
Approval date [5]
5955
0
20/05/2005
Query!
Ethics approval number [5]
5955
0
6/10/05
Query!
Ethics committee name [6]
5956
0
ACT Health Human Research Ethics Committee
Query!
Ethics committee address [6]
5956
0
GPO Box 825 Canberra ACT
Query!
Ethics committee country [6]
5956
0
Australia
Query!
Date submitted for ethics approval [6]
5956
0
01/02/2000
Query!
Approval date [6]
5956
0
13/03/2000
Query!
Ethics approval number [6]
5956
0
ETH.2/00.54 refers
Query!
Summary
Brief summary
This is a multi-centre, blinded placebo-controlled randomised trial of long-term antibiotics in children. Patients will be randomly allocated to either low dose cotrimoxazole or placebo and followed for 12 months. Randomisation will be performed centrally by the NHMRC Clinical Trials Centre with dynamic balancing of important confounders and stratified by vesicoureteric reflux. Treatment allocation will be concealed. A total of 780 participants will be drawn from children routinely given long-term antibiotics, either because of their age (infants), what is thought to be a predisposing abnormality (vesicoureteric reflux), or because of recurrent infections. Children will be monitored at 3, 6, 9 and 12 month clinics. The primary outcome is repeat symptomatic microbiologically proven urinary tract infection
Query!
Trial website
http://www.kidney-research.org/privent.html
Query!
Trial related presentations / publications
N Engl J Med 2009;361:1748-59.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
28953
0
Prof Jonathan Craig
Query!
Address
28953
0
The Childrens Hospital at Westmead, Locked Bag 4001, Westmead, NSW 2145
Query!
Country
28953
0
Australia
Query!
Phone
28953
0
0298451492
Query!
Fax
28953
0
Query!
Email
28953
0
[email protected]
Query!
Contact person for public queries
Name
12110
0
Professor Jonathan Craig
Query!
Address
12110
0
The Childrens Hospital at Westmead, Locked Bag 4001, Westmead, NSW 2145
Query!
Country
12110
0
Australia
Query!
Phone
12110
0
0298453431
Query!
Fax
12110
0
0298451491
Query!
Email
12110
0
[email protected]
Query!
Contact person for scientific queries
Name
3038
0
Professor Jonathan Craig
Query!
Address
3038
0
The Childrens Hospital at Westmead, Locked Bag 4001, Westmead, NSW 2145
Query!
Country
3038
0
Australia
Query!
Phone
3038
0
0298453431
Query!
Fax
3038
0
0298451491
Query!
Email
3038
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF